Baseline epigenetics as a biomarker of mepolizumab response in severe asthma
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Biologic treatment options have expanded considerably for severe asthma, transforming patient management, but only ~70% of patients respond to the treatment following standard criteria.
This preliminary study utilized data collected in the Wessex AsThma CoHort of difficult asthma (WATCH) study. DNAm was measured in n=15 severe asthma patients at baseline, i.e., before mepolizumab (MEPO), an interleukin-5 receptor antagonist, was administered and the response to MEPO was analyzed. We aimed to assess the potential of DNA methylation as a feasible biomarker to predict responses to MEPO among severe asthma patients.
Our preliminary findings suggested that pre-biologic DNA methylation as a predictor of a patient’s response status may outperform pre-biologic blood eosinophils cell counts.
